Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results [Yahoo! Finance]
Marinus Pharmaceuticals, Inc. (MRNS)
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.marinuspharma.com/investor-relations
Company Research
Source: Yahoo! Finance
Net Loss : Reported a net loss of $141.405 million for the full year 2023, compared to a net loss of $19.816 million in the previous year. Research and Development Expenses : R&D expenses rose to $99.388 million in 2023, up from $79.912 million in 2022. Total Assets : Decreased to $170.908 million as of December 31, 2023, down from $259.518 million the previous year. Cash Position : Cash and cash equivalents reduced to $120.572 million, compared to $240.551 million at the end of 2022. Warning! GuruFocus has detected 6 Warning Signs with MRNS. On March 5, 2024, Marinus Pharmaceuticals Inc ( NASDAQ:MRNS ) released its 8-K filing , detailing the company's financial results for the fourth quarter and the full year ended December 31, 2023. Marinus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for epilepsy and neuropsychiatric disorders, has reported several key financial and business updates. Marin
Show less
Read more
Impact Snapshot
Event Time:
MRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNS alerts
High impacting Marinus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MRNS
News
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Marinus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MRNSAccesswire
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Investors who lost money on Marinus Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - MRNSAccesswire
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
MRNS
Earnings
- 3/5/24 - Miss
MRNS
Sec Filings
- 4/25/24 - Form SC
- 4/19/24 - Form SC
- 4/4/24 - Form DEFA14A
- MRNS's page on the SEC website